GRCE GRACE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, GRACE THERAPEUTICS INC reported revenue of n/a, net income of −$15.8M and diluted EPS of −$0.91; for the fiscal year ended March 2026 revenue was n/a.
GRCE annual revenue and earnings
- Fiscal year ended Mar 2026: revenue n/a, gross profit n/a, operating income −$11.1M, net income −$7.79M (margin n/a), EPS −$0.47
- Fiscal year ended Mar 2025: revenue n/a, gross profit n/a, operating income −$16.7M, net income −$9.57M (margin n/a), EPS −$0.79
- Fiscal year ended Mar 2024: revenue n/a, gross profit n/a, operating income −$12.9M, net income −$12.9M (margin n/a), EPS −$1.35
- Fiscal year ended Mar 2023: revenue n/a, gross profit n/a, operating income −$52.2M, net income −$42.4M (margin n/a), EPS −$5.71
- Fiscal year ended Mar 2022: revenue $100M, gross profit n/a, operating income −$15.6M, net income −$9.82M (margin -9.8%), EPS −$0.27
GRCE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$15.8M, EPS −$0.91
- Quarter ended Mar 31, 2026 (from the annual report): revenue n/a, net income −$1.18M, EPS −$0.06
- Quarter ended Dec 31, 2025: revenue n/a, net income −$2.32M, EPS −$0.14
- Quarter ended Sep 30, 2025: revenue n/a, net income −$938K, EPS −$0.06
- Quarter ended Jun 30, 2025: revenue n/a, net income −$3.36M, EPS −$0.21
- Quarter ended Mar 31, 2025 (from the annual report): revenue n/a, net income $636K, EPS $0.11
- Quarter ended Dec 31, 2024: revenue n/a, net income −$4.16M, EPS −$0.36
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.43M, EPS −$0.30
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.62M, EPS −$0.24
- Quarter ended Mar 31, 2024 (from the annual report): revenue n/a, net income −$3.17M, EPS −$0.17
- Quarter ended Dec 31, 2023: revenue n/a, net income −$2.39M, EPS −$0.21
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.27M, EPS −$0.43
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.02M, EPS −$0.54
- Quarter ended Mar 31, 2023 (from the annual report): revenue n/a, net income −$29.1M, EPS −$3.92
- Quarter ended Dec 31, 2022: revenue n/a, net income −$3.89M, EPS −$0.52
- Quarter ended Sep 30, 2022: revenue n/a, net income −$4.93M, EPS −$0.66
- Quarter ended Jun 30, 2022: revenue n/a, net income −$4.52M, EPS −$0.61
- Quarter ended Mar 31, 2022 (from the annual report): revenue n/a, net income −$3.90M, EPS −$0.03
- Quarter ended Dec 31, 2021: revenue $0, net income −$3.78M, EPS −$0.09
- Quarter ended Sep 30, 2021: revenue n/a, net income $981K, EPS −$0.03
GRCE cash flow, buybacks and dividends
- Fiscal year ended Mar 2026: operating cash flow −$8.87M, share buybacks n/a
- Fiscal year ended Mar 2025: operating cash flow −$14.9M, share buybacks n/a
- Fiscal year ended Mar 2024: operating cash flow −$12.3M, share buybacks n/a
- Fiscal year ended Mar 2023: operating cash flow −$15.9M, share buybacks n/a
- Fiscal year ended Mar 2022: operating cash flow −$17.2M, share buybacks n/a
GRCE balance sheet
- Jun 30, 2026: cash $13.8M, total assets $50.1M, total liabilities $1.86M, shareholders' equity $48.2M
- Mar 31, 2026: cash $17.0M, total assets $66.7M, total liabilities $2.76M, shareholders' equity $63.9M
- Dec 31, 2025: cash $18.7M, total assets $68.5M, total liabilities $3.60M, shareholders' equity $64.9M
- Sep 30, 2025: cash $16.9M, total assets $66.6M, total liabilities $3.76M, shareholders' equity $62.8M
- Jun 30, 2025: cash $20.0M, total assets $69.8M, total liabilities $6.26M, shareholders' equity $63.6M
- Mar 31, 2025: cash $22.1M, total assets $72.0M, total liabilities $5.38M, shareholders' equity $66.6M
- Dec 31, 2024: cash $11.1M, total assets $61.2M, total liabilities $9.09M, shareholders' equity $52.1M
- Sep 30, 2024: cash $15.2M, total assets $65.3M, total liabilities $9.22M, shareholders' equity $56.1M
Is GRCE profitable?
No. GRACE THERAPEUTICS INC lost $20.2M over the last four quarters.
What is GRCE's EPS?
Diluted earnings per share over the last four quarters were −$1.17; −$0.91 in the latest quarter.